Magnetar Financial LLC Acquires 56,174 Shares of Revance Therapeutics, Inc. (NASDAQ:RVNC)

Magnetar Financial LLC lifted its holdings in shares of Revance Therapeutics, Inc. (NASDAQ:RVNC) by 2.2% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 2,556,345 shares of the biopharmaceutical company’s stock after purchasing an additional 56,174 shares during the period. Magnetar Financial LLC owned 2.45% of Revance Therapeutics worth $7,771,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. FORA Capital LLC bought a new stake in shares of Revance Therapeutics during the 3rd quarter valued at about $54,000. Dynamic Technology Lab Private Ltd bought a new position in Revance Therapeutics in the third quarter worth approximately $88,000. GSA Capital Partners LLP bought a new position in Revance Therapeutics in the third quarter worth approximately $108,000. Virtu Financial LLC bought a new position in Revance Therapeutics in the third quarter worth approximately $120,000. Finally, Intech Investment Management LLC bought a new position in Revance Therapeutics in the third quarter worth approximately $231,000. Institutional investors own 97.70% of the company’s stock.

Revance Therapeutics Stock Performance

Shares of RVNC opened at $3.65 on Thursday. The company has a market capitalization of $381.02 million, a price-to-earnings ratio of -1.89 and a beta of 0.90. The stock has a 50 day moving average of $3.61 and a 200 day moving average of $4.29. Revance Therapeutics, Inc. has a 12 month low of $2.30 and a 12 month high of $6.65.

Analyst Ratings Changes

Several research analysts have issued reports on RVNC shares. Needham & Company LLC reiterated a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Mizuho dropped their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. StockNews.com assumed coverage on Revance Therapeutics in a report on Tuesday. They issued a “hold” rating on the stock. Finally, Barclays dropped their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Nine analysts have rated the stock with a hold rating and one has given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average price target of $8.39.

Revance Therapeutics Profile

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.